By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche announced today the clearance of its cobas HPV test by the US Food and Drug Administration.

The test, the company said, identifies women who are at greatest risk for developing cervical cancer, and is the only cervical cancer screening test approved by the FDA that allows HPV 16 and 18 genotyping concurrently with high-risk HPV testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.